The pharmaceutical industry depends heavily on accurate product labeling, especially when it comes to shelf life and expiry date. Yet, these two terms remain frequently misunderstood, leading to compliance gaps, internal errors, and regulatory red flags. In this tutorial, we’ll uncover the most common myths surrounding these concepts and provide actionable ways to eliminate them through clear documentation, staff training, and regulatory alignment.
Why Do These Misconceptions Persist?
Despite stringent regulatory compliance norms and training efforts, confusion between shelf life and expiry arises due to overlapping definitions, inconsistent communication, and inadequate function-specific training. These misconceptions are particularly dangerous during labeling, stability data interpretation, and audit responses.
Let’s break down the myths and replace them with evidence-backed facts aligned with global standards like ICH guidelines.
Myth 1: Shelf Life and Expiry Date Are Interchangeable
Reality: Shelf life is the time a drug remains within approved specifications. Expiry date is the final, legally enforceable date a drug can be used. While expiry is derived from shelf life, the terms serve different regulatory and operational purposes.
- Shelf life guides internal stability decisions
- Expiry date is what appears on labels and affects product use
This confusion often leads to errors in documentation and ERP labeling systems.
Myth 2: Expiry
Reality: Expiry extension requires robust supporting data—typically, real-time stability results following ICH Q1E guidelines—and prior regulatory approval. Any extension made without submission or justification is a critical GMP violation.
Case example: A company extended expiry to 36 months based on an assumption that data trends would hold. During inspection, USFDA flagged the deviation, resulting in a warning letter.
Myth 3: Beyond Use Date and Expiry Date Are the Same
Reality: Beyond Use Date (BUD) refers to the last date a compounded or reconstituted product can be used. This is different from the manufacturer-set expiry date, which is based on long-term stability studies.
- BUD is shorter and assigned post-opening or compounding
- Expiry is fixed and printed on sealed product packages
Mislabeling BUD as expiry can result in improper usage timelines and miscommunication in clinical trial protocols.
Myth 4: Expiry Date Can Be Calculated Manually for Each Batch
Reality: Expiry date must be derived from validated, documented shelf life and calculated via ERP or other GMP-controlled systems. Manual calculations pose a major risk for inconsistency and labeling errors.
Use of validated electronic systems with locked expiry logic is a best practice in process validation and labeling compliance.
Myth 5: Stability Failures After Expiry Don’t Impact Compliance
Reality: Post-expiry stability failures (even if discovered through internal testing) reflect on the accuracy of originally assigned shelf life and expiry. These must be investigated, reported, and, if needed, used to revise ongoing stability protocols or labeling practices.
Myth 6: Expiry Date Format Is Universal Across All Countries
Reality: While many regulatory bodies prefer the “MM/YYYY” format, others (e.g., certain ASEAN or Latin American countries) require “DD/MM/YYYY” or “Month Year” textual formats. Failing to comply with local standards can lead to market-specific non-compliance.
- ✅ Always cross-check with regional regulatory labeling guidelines
- ✅ Implement artwork variations per country submission
- ✅ Audit all language versions for consistency
Myth 7: Recalled Products Can Be Re-labeled with New Expiry
Reality: Relabeling recalled drugs with a new expiry without appropriate regulatory approval and fresh stability data is a GMP breach. In most jurisdictions, recalled lots cannot be reused or re-labeled unless stability integrity and traceability are demonstrated.
Proper change control and documentation are essential before any re-issuance or relabeling.
Addressing Misconceptions Through Training
Dispelling these myths requires structured, ongoing training programs across departments:
- 🎯 Monthly refresher trainings on labeling and expiry handling
- 🎯 Department-specific quizzes to evaluate understanding
- 🎯 Use of real case studies from warning letters and audits
- 🎯 Simulation exercises involving mock recalls or labeling reviews
Integrating such initiatives within the pharma organization improves long-term compliance outcomes.
Checklist to Combat Shelf Life and Expiry Myths
- ✅ Include definitions in all GMP and labeling SOPs
- ✅ Maintain change logs for expiry updates in ERP
- ✅ Implement dual verification for expiry calculations
- ✅ Include expiry validation in annual product review
- ✅ Align artwork approval with regulatory filings
Regular checklist use prevents assumptions from entering critical processes like labeling, stability testing, and market release.
Conclusion
In the pharmaceutical industry, where precision is paramount, misconceptions about shelf life and expiry date can have serious consequences—from product recalls to patient risk. Educating teams, using validated systems, and maintaining cross-functional alignment are key strategies for eliminating these myths.
By recognizing common misunderstandings and proactively correcting them, pharma companies can ensure better SOP training, improved regulatory trust, and stronger internal compliance frameworks.